Serum Resistin and Inflammatory and Endothelial Activation Markers in Obese Adolescents

Pediatric Sport Medicine and Obesity Care Program, Service of Pediatric Specialties, Department of Child and Adolescent, University Hospitals of Geneva and University of Geneva, Switzerland.
The Journal of pediatrics (Impact Factor: 3.79). 08/2012; 161(6). DOI: 10.1016/j.jpeds.2012.05.063
Source: PubMed


To assess the level of serum resistin in obese and lean children and to establish a relationship with circulating inflammatory and vascular markers.

Study design:
This is a cross-sectional study including 67 obese and 62 lean children (mean age 10.9 ± 2.8 years, age range 5.4-16.6 years). We assessed circulating hormones (insulin, leptin, insulin-like growth factor 1), markers of inflammation (resistin, high sensitivity C-reactive protein, interleukin-6, chemokine ligand 2), and endothelial cell activation (vascular and intercellular adhesion molecules: vascular cell adhesion molecule 1 and intercellular adhesion molecule; E-selectin; P-selectin; endothelin 1).

Body weight, body mass index (BMI), insulin, leptin, high-sensitivity C-reactive protein, vascular adhesion molecule 1, and E-selectin levels were significantly higher in obese than in lean subjects. Resistin was similar among the groups in the prepubertal period, but increased significantly in the obese adolescents (18.6 ± 24.9) compared with lean subjects (7.9 ± 10.7 ng/mL; P = .038). Resistin was not associated with BMI z score (P > .05). Subjects with resistin levels above 9 (ng/mL) had higher concentration of interleukin-6, chemokine ligand 2, endothelin-1, and insulin-like growth factor 1 but not of leptin, insulin, or BMI.

Resistin was increased in obese adolescents independently of the quantity of the adipose tissue. In this population, increased resistin levels were related to inflammation and endothelial activation. We may hypothesize that interventions aiming to diminish resistin expression may slow down atherogenesis in adolescents.

Download full-text


Available from: Albane B R Maggio,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Resistin is a recently described adipokine which is expressed in low levels in human adipose tissue, pulmonary tissue and resting endothelial cells, and in high levels in mononuclear leukocytes, macrophages, and spleen and bone marrow cells. Serum levels of resistin have been found to be elevated in obese subjects and in subjects with insulin resistance and diabetes mellitus (DM). There is evidence that resistin is related to a variety of diseases, including rheumatoid arthritis, systemic lupus erythematous, sepsis, asthma and allergic rhinitis. A possible role of resistin has been documented in pathological metabolic conditions observed in children and adolescents, but the data are conflicting. This review summarizes the currently available data concerning the role of resistin in metabolic abnormalities and diseases in children and adolescents.
    Archives of Hellenic Medicine 30(6):700-706.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Previous few studies have shown that resistin is significantly elevated in breast cancer (BC) patients. Therefore, we investigated whether serum resistin could be used as a potential diagnostic and prognostic tool for postmenopausal BC (PBC), taking into account clinicopathological features, serum tumor markers, anthropometric, metabolic, and, for the first time, inflammatory parameters. Methods: Serum resistin, tumor markers (CA 15-3 and CEA), metabolic, anthropometric and inflammatory parameters (TNF-α, IL-6, hsCRP) were determined in 103 postmenopausal women with incident, pathologically confirmed, invasive BC, 103 controls matched on age and time of diagnosis, and 51 patients with benign breast lesions (BBL). Results: Mean serum resistin was significantly higher in cases than in controls and patients with BBL (p<0.001). In patients, resistin was significantly associated with tumor and inflammatory markers, cancer stage, tumor size, grade and lymph node invasion but not with anthropometric, metabolic parameters and hormone receptor status. Multivariable regression analysis revealed that serum IL-6 (p=0.02) and cancer stage (p=0.048) were the strongest determinants of serum resistin in cases adjusting for demographic, metabolic and clinicopathological features. Although resistin's diagnostic performance was low based on ROC curve analysis [0.72, 95% CI: 0.64-0.79], it could, however, represent a BC biomarker reflecting advanced disease stage and inflammatory state. Conclusion: Further prospective and longitudinal studies are needed to evaluate whether serum resistin could be used as a prognostic tool in BC monitoring and management. More research is essential to elucidate resistin's ontological role in the association between obesity, representing a chronic low-grade subclinical inflammation, and PBC.
    Clinical biochemistry 01/2013; 46(7-8). DOI:10.1016/j.clinbiochem.2013.01.001 · 2.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: The magnitude of lifetime risk of cardiovascular disease (CVD) has radically increased along with the high prevalence of obesity in children. The spotlight is now on dysfunctional adiposity as a precursor for the development of premature CVD. As full-blown CVD is not present in childhood, there is a critical need for surrogate markers to best assess, predict, and treat the children who are vulnerable to developing CVD. Recent findings: Accumulation of excess fat mass can be conceived as a derangement in the balance between energy intake and expenditure. This appears to provoke various structural and metabolic alterations leading to adipocyte dysfunction, with important cardiovascular health consequences. Subclinical inflammation, insulin resistance, oxidative stress, and endothelial dysfunction appear to play important roles early in the clinical course of obesity. Summary: Associations between biomarkers and noninvasive measures of early atherosclerosis in children continue to emerge and several biomarkers appear to be promising. At present, there are no explicit data to recommend any of these biomarkers as a routine clinical marker of CVD in children. More work is needed to validate these biomarkers and to improve understanding of their role in CVD risk prediction in the pediatric population.
    Current opinion in cardiology 01/2013; 28(2). DOI:10.1097/HCO.0b013e32835dd0ce · 2.70 Impact Factor
Show more